Uchida Y, Kawada M, Sawanobori K, Sonoki H, Inoue K, Mizuno K, Itou T, Tabunoki Y, Tsukamoto M, Ohashi Y, Kyotani Y, Shimizu N, Fujii M, Nakamura M
Clinical Physiology and Cardiovascular Center, Toho University Hospital at Sakura, Chiba, Japan.
Arzneimittelforschung. 1998 Mar;48(3):219-31.
The cardiovascular effects of (2RS,3SR)-2-aminomethyl-2,3,7,8- tetrahydro-2,3,5,8,8-pentamethyl-6H-furo[2,3-e]indol-7-one hydrochloride (CAS 170684-14-7, UK-1745), a novel cardiotonic agent, were investigated using in vitro and in vivo preparations. In paced left atria isolated from guinea pigs, both UK-1745 and vesnarinone (CAS 81840-15-5) showed a concentration-dependent positive inotropic effect. In spontaneously beating guinea pig right atria, both agents caused only a minimal chronotropic effect. In isolated, blood-perfused canine papillary muscle preparations, UK-1745 and vesnarinone injected intra-arterially into the anterior septal artery (ASA) increased the developed tension in a dose-dependent manner. In isolated, blood-perfused canine sinoatrial node preparations, both agents injected into the right coronary artery (RCA) did not cause any appreciable changes in the sinus rate. UK-1745 increased the blood flow through the ASA and the RCA in a dose-dependent manner, whereas vesnarinone did not. In anesthetized open-chest dogs, UK-1745 injected intravenously increased cardiac contractility and cardiac output, and decreased left ventricular end-diastolic pressure, systemic vascular resistance and heart rate. In experimentally induced acute heart failure in anesthetized open-chest dogs, intravenously injected UK-1745 effectively improved hemodynamic functions. In conscious instrumented dogs, orally administered UK-1745 increased LV dP/dtmax with insignificant changes in systemic blood pressure and heart rate. In mice, orally administered UK-1745 protected the development of ventricular fibrillation induced by chloroform inhalation, whereas vesnarinone did not. Thus, in respect of inotropic and chronotropic effects, UK-1745 closely resembled vesnarinone, but differed from vesnarinone in respect of coronary vasodilating and antiarrhythmic effects. The results suggest that UK-1745 is a novel positive inotropic agent with vasodilatory and antiarrhythmic properties, without significant chronotropic action, and may be beneficial for the treatment of congestive heart failure.
使用体外和体内实验制剂,对新型强心剂(2RS,3SR)-2-氨甲基-2,3,7,8-四氢-2,3,5,8,8-五甲基-6H-呋喃并[2,3-e]吲哚-7-酮盐酸盐(CAS 170684-14-7,UK-1745)的心血管效应进行了研究。在从豚鼠分离的起搏左心房中,UK-1745和维司力农(CAS 81840-15-5)均呈现浓度依赖性正性肌力作用。在自发搏动的豚鼠右心房中,两种药物仅引起最小的变时作用。在分离的、血液灌注的犬乳头肌制剂中,经动脉注射到前间隔动脉(ASA)中的UK-1745和维司力农以剂量依赖性方式增加了收缩张力。在分离的、血液灌注的犬窦房结制剂中,注入右冠状动脉(RCA)的两种药物均未引起窦性心率的任何明显变化。UK-1745以剂量依赖性方式增加了通过ASA和RCA的血流量,而维司力农则没有。在麻醉的开胸犬中,静脉注射UK-1745可增加心脏收缩力和心输出量,并降低左心室舒张末期压力、全身血管阻力和心率。在麻醉的开胸犬实验性诱导的急性心力衰竭中,静脉注射UK-1745有效改善了血流动力学功能。在清醒的仪器化犬中,口服UK-1745可增加左心室dp/dtmax,而全身血压和心率无明显变化。在小鼠中,口服UK-1745可保护吸入氯仿诱导的心室颤动的发生,而维司力农则不能。因此,就正性肌力和变时作用而言,UK-1745与维司力农非常相似,但在冠状动脉扩张和抗心律失常作用方面与维司力农不同。结果表明,UK-1745是一种新型的具有血管舒张和抗心律失常特性的正性肌力药物,无明显的变时作用,可能对治疗充血性心力衰竭有益。